AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Stock analysts at Jefferies Group upped their FY2017 earnings per share (EPS) estimates for AcelRx Pharmaceuticals in a research report issued on Tuesday. Jefferies Group analyst M. Andrews now expects that the specialty pharmaceutical company will post earnings of ($1.00) per share for the year, up from their previous estimate of ($1.02). Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for AcelRx Pharmaceuticals’ Q4 2017 earnings at ($0.21) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($0.85) EPS, FY2020 earnings at ($1.14) EPS and FY2021 earnings at ($0.93) EPS.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/16/fy2017-eps-estimates-for-acelrx-pharmaceuticals-inc-boosted-by-analyst-acrx.html.

ACRX has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Roth Capital set a $13.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $6.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. Stifel Nicolaus raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $6.83.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at $1.90 on Thursday. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

In other news, insider Pamela P. Palmer bought 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The shares were bought at an average price of $2.95 per share, with a total value of $29,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the transaction, the insider now directly owns 16,379 shares in the company, valued at approximately $86,644.91. The disclosure for this sale can be found here. In the last three months, insiders acquired 72,000 shares of company stock worth $178,980. 28.10% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Perennial Advisors LLC bought a new position in AcelRx Pharmaceuticals in the third quarter valued at about $138,000. Virtu KCG Holdings LLC lifted its holdings in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the period. LMR Partners LLP bought a new position in AcelRx Pharmaceuticals in the second quarter valued at about $319,000. Bank of New York Mellon Corp lifted its holdings in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after acquiring an additional 6,942 shares during the period. Finally, WealthTrust Axiom LLC lifted its holdings in AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after acquiring an additional 70,000 shares during the period. 23.09% of the stock is currently owned by institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.